Cognision Partners with Anavex for Phase 2 Study of ANAVEX®3-71 Compound

FOR IMMEDIATE RELEASE

Anavex (AVXL) Partners with Cognision for Study of ANAVEX®3-71 in Subjects with Schizophrenia

4/22/2024 - Cognision, providers of advanced neurobiomarker technology, announces its partnership with Anavex Life Sciences Corp. (Nasdaq: AVXL), in a phase 2 clinical trial of ANAVEX®3-71 in subjects with schizophrenia.

ANAVEX®3-71 is a therapeutic agent with a dual mechanism of action, a SIGMAR1 receptor agonist and M1 positive allosteric modulator. This novel mechanism offers the potential to treat all symptom domains of schizophrenia -- positive symptoms (hallucinations and delusions), negative symptoms (difficulty enjoying life and withdrawal from others), and cognitive impairment (deficits in memory, concentration, and decision-making) -- without the side effects of standard-of-care antipsychotics. ANAVEX®3-71's ability to modulate both SIGMAR1 and M1 receptors is potentially expected to address disruptions to neuronal homeostasis observed in individuals with schizophrenia, upstream of the targets leveraged by standard-of-care medications.

Anavex chose to partner with Cognision and utilize the COGNISION® System because of the system's ability to precisely measure drug-induced changes in brain function in the small cohorts commonly used in early-phase trials. These measures are obtained during electroencephalographic (EEG) and event-related potential (ERP) testing sessions after subjects are dosed with either ANAVEX®3-71 or a placebo. With this EEG/ERP technology, potentially therapeutic effects of novel compounds can be detected at an early stage in a clinical trial program.

"We are thrilled to partner with Anavex in this very important trial," said Matt Bevin, CEO at Cognision. "Our advanced EEG/ERP technology will provide early insights on the neural response to ANAVEX®3-71 in individuals with schizophrenia, possibly paving the way for more effective and targeted therapeutic interventions for this very vulnerable population."

Anavex is leveraging their participation in the ERP Biomarker Qualification Consortium (www.erpbiomarkers.org), a precompetitive consortium involving ten pharmaceutical companies. The objective of the consortium is to optimize and standardize EEG/ERP techniques for widespread use in clinical trials of drugs targeting brain function. The specific measures used in ANAVEX®3-71 trial were previously validated for use with schizophrenic subjects in a consortium sponsored trial, https://clinicaltrials.gov/study/NCT04025502, and were peer reviewed then published Cecchi, et al, 2023 (https://www.sciencedirect.com/science/article/pii/S0920996423000609).

Cognision
1044 E. Chestnut St.
Louisville KY 40204
Nathan Alvarado
Director of Business Development
502-561-9040
nalvarado@cognision.com
www.erpbiomarkers.org
www.cognision.com

About Cognision

Cognision is the leading provider of advanced EEG/ERP technology used in pharma-sponsored clinical trials. With the COGNISION® System, pharma companies can gain near-realtime insights into the neural effects of brain-targeting compounds. The COGNISION® System is also used by clinicians to evaluate patients suffering from Alzheimer's disease and concussion.

This release was published on openPR.